What Is It, and Why Does It Matter?
Utebzi (tebipenem pivoxil) is an oral carbapenem antibiotic. It blocks proteins that bacteria use to build their cell walls, which stops them from growing, allowing your body to clear the infection.
The FDA approved Utebzi to treat complicated urinary tract infections (cUTIs), including kidney infection (pyelonephritis), in adults with limited or no other oral choices. It targets certain bacteria, such as Escherichia coli and Klebsiella species, when testing shows they are susceptible. This approval is notable because Utebzi is currently the only carbapenem available as a pill in the U.S.
Until now, medicines in this class were given only through a vein. Having an effective oral option may help some adults avoid inpatient IV treatment.
cUTIs are common and can be serious. In the U.S., they happen more than 3 million times each year, and drug‑resistant germs are often involved. Carbapenems are important for hard‑to‑treat infections, but they have been IV‑only until this approval. Utebzi also received priority review, fast track, and Qualified Infectious Disease Product (QIDP) status, programs the FDA uses to speed the review of important antibiotics.
Why Was It Approved?
Utebzi earned approval because, in a study of adults in the hospital with cUTIs (including kidney infection), it worked about as well as a standard IV carbapenem. People took oral Utebzi every six hours for about seven to 10 days, or they received IV imipenem‑cilastatin for the same period. Success combined symptom relief with clearing the bacteria causing the infection.
Results were similar in both groups. Utebzi met the bar for “non‑inferior,” which means it was not worse than the IV medicine by the study’s preset margin. This showed that an oral carbapenem could work as well as a commonly used IV option in this setting.
The most common side effects with Utebzi were diarrhea, headache, nausea, stomach pain, higher liver tests, and Clostridioides difficile infection. Serious allergic reactions have been reported with beta‑lactam and carbapenem antibiotics. Seizures and other nervous system effects have also been seen with carbapenems, including Utebzi. Tell your health care provider if you have a history of seizures or a brain condition.
In the same study, the overall safety looked much like that of the IV type. Diarrhea and headache were the most frequent issues and were generally mild to moderate. This approval is for adults only; safety and effectiveness in people younger than 18 have not been established.
What Do I Need to Know?
The usual adult dose is taken by mouth every six hours for seven to 10 days. You can take it with or without food. Swallow the tablets whole. If you miss a dose, take it when you remember, unless it is close to the time to take the next dose. Do not take two doses at once.
Your dose may change if your kidneys do not work well. Dosing for people on dialysis has not been defined. Use is not recommended when certain kidney measures are very high because drug levels in your body may be too low to work well.
Do not take Utebzi if you have ever had a serious allergic reaction to this drug or to other beta‑lactam antibacterial drugs. Do not use it if you have primary or secondary carnitine deficiency, or certain metabolic conditions that can cause low carnitine. Because this medicine can lower carnitine during treatment, do not take it longer than directed.
Do not use Utebzi with valproic acid or divalproex sodium. This combination can lower valproic acid levels and raise the chance of seizures. Your health care provider may choose a different antibiotic if you take these medicines. Call your health care provider right away if you have severe or ongoing diarrhea, belly cramps, or fever. Antibiotics, including Utebzi, can cause a serious bowel infection called C. difficile.
If you receive Utebzi near the time you deliver a baby, your newborn’s screening may show a false positive for a rare condition called isovaleric acidemia. If this happens, follow up with your baby’s care team for confirmatory testing.
Drug companies expect Utebzi to be available in the U.S. by the end of 2026. If you think you have a urinary infection, or your symptoms are not improving, contact your health care provider. Your care team will consider your medical history, kidney function, and other medicines to decide whether this treatment is an option for you.